SCHEMBL20848101

SCHEMBL20848101

CCOC(=O)[C@H]1CCCN(C(=O)C(CC)Oc2ccc3c(-c4ccccc4Cl)cc(=O)oc3c2)C1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ KMT2A Q03164 6/20 0.48
▸ MEN1 O00255 5/20 0.48
▸ MAPT P10636 2/20 0.48
▸ RAB9A P51151 3/20 0.47
▸ TSHR P16473 2/20 0.46
▸ AR P10275 1/20 0.45
▸ HPGD P15428 3/20 0.44
▸ HTT P42858 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ RECQL P46063 1/20 0.43
▸ NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30055832 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL30055214 0.92 MAPT (0.57) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL20848109 0.92 MAPT (0.57) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL20839050 0.92 RAB9A (0.46) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL30055555 0.92 RAB9A (0.46) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL30360913 0.88 CA12 (0.48) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL26503877 0.88 CA12 (0.48) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL20848110 0.85 CYP3A4 (0.56) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL30056612 0.85 CYP3A4 (0.56) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL28897158 0.84 KMT2A (0.48) ALDH1A1KDM4EKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111386261-B Coumarin derivatives, process for their preparation and their use in the treatment of cancer 利德发现中心有限责任公司 2024-03-22 — — CN claimed
CN-111386261-A Coumarin derivatives, preparation method thereof and application thereof in cancer treatment 利德发现中心有限责任公司 2020-07-07 — — CN claimed
CN-111386261-B Coumarin derivatives, process for their preparation and their use in the treatment of cancer 利德发现中心有限责任公司 2024-03-22 — — CN disclosed
EP-3684762-B1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2023-05-03 — — EP disclosed
US-11111238-B2 Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2021-09-07 — — US disclosed
US-20200291011-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-09-17 — — US disclosed
CN-111386261-A Coumarin derivatives, preparation method thereof and application thereof in cancer treatment 利德发现中心有限责任公司 2020-07-07 — — CN disclosed
WO-2019057821-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2019-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11111238-B2 Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer POLRMT, UQCRC2, UQCRC1 ALDH1A1 1261/4885KDM4E 2362/4885KMT2A 3352/4885
US-20200291011-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER POLRMT, UQCRC2, UQCRC1 ALDH1A1 1261/4885KDM4E 2362/4885KMT2A 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback